Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Guardant Health, Inc. (NASDAQ:GH) have received an average recommendation of “Moderate Buy” from the twenty-four analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and twenty-three have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $77.1429.

Several equities analysts recently issued reports on GH shares. William Blair restated an “outperform” rating on shares of Guardant Health in a research report on Thursday, September 25th. Guggenheim boosted their target price on Guardant Health from $56.00 to $67.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Citigroup upped their price target on Guardant Health from $65.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Stifel Nicolaus set a $73.00 price objective on shares of Guardant Health in a research report on Thursday, September 25th. Finally, Leerink Partners upped their price objective on shares of Guardant Health from $70.00 to $75.00 and gave the stock an “outperform” rating in a research report on Thursday, September 25th.

Insider Buying and Selling

In other Guardant Health news, Director Medina Manuel Hidalgo sold 2,165 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40. Following the transaction, the director owned 851 shares in the company, valued at approximately $46,090.16. The trade was a 71.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Helmy Eltoukhy sold 300,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total value of $17,835,000.00. Following the completion of the sale, the chief executive officer directly owned 2,123,499 shares of the company’s stock, valued at $126,242,015.55. This represents a 12.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 313,161 shares of company stock valued at $18,996,062 over the last ninety days. Corporate insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Sound Income Strategies LLC purchased a new stake in shares of Guardant Health during the 3rd quarter worth $38,000. IFP Advisors Inc increased its holdings in shares of Guardant Health by 120.1% in the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after purchasing an additional 334 shares in the last quarter. Signaturefd LLC lifted its stake in shares of Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after purchasing an additional 213 shares during the period. Allworth Financial LP boosted its holdings in Guardant Health by 358.4% during the second quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after buying an additional 552 shares in the last quarter. Finally, Optiver Holding B.V. grew its position in Guardant Health by 153.5% during the third quarter. Optiver Holding B.V. now owns 768 shares of the company’s stock worth $48,000 after buying an additional 465 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Price Performance

GH stock opened at $108.13 on Monday. The company has a market cap of $13.63 billion, a price-to-earnings ratio of -33.68 and a beta of 1.56. The company has a fifty day moving average price of $80.11 and a 200 day moving average price of $61.13. Guardant Health has a 12 month low of $29.91 and a 12 month high of $112.43.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. During the same quarter last year, the business earned ($0.88) earnings per share. Guardant Health’s revenue was up 38.5% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Guardant Health will post -2.9 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.